DGX

196.31

0.46% 1.29

Handel nachbörslich: 196.32 0.010 +0.01%

Quest Diagnostics Inc (DGX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$195.02

Offen:

$194.22

24-Stunden-Volumen:

1.96M

Relative Volume:

1.99

Marktkapitalisierung:

$21.73B

Einnahmen:

$11.04B

Nettoeinkommen (Verlust:

$1.04B

KGV:

22.40

EPS:

8.7626

Netto-Cashflow:

$1.36B

1W Leistung:

+1.56%

1M Leistung:

+0.33%

6M Leistung:

+2.89%

1J Leistung:

+19.60%

1-Tages-Spanne:

$191.63

$196.77

1-Wochen-Bereich:

$190.23

$196.53

52-Wochen-Spanne:

$160.02

$213.50

Quest Diagnostics Inc Stock (DGX) Company Profile

Firmenname

Quest Diagnostics Inc

Sektor

Healthcare (1119)

Branche

Diagnostics & Research (51)

Telefon

(973) 520-2700

Adresse

500 PLAZA DRIVE, SECAUCUS

Mitarbeiter

57,000

Twitter

@QuestDX

Nächster Verdiensttermin

2026-04-21

Neueste SEC-Einreichungen

DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DGX Quest Diagnostics Inc	196.31	21.59B	11.04B	1.04B	1.36B	8.7626
TMO Thermo Fisher Scientific Inc	526.02	195.70B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	195.50	137.82B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	583.06	46.80B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.96	34.44B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	335.61	32.18B	3.17B	642.63M	516.49M	10.77

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-30	Hochstufung	Barclays	Equal Weight → Overweight
2025-08-25	Herabstufung	Robert W. Baird	Outperform → Neutral
2025-04-02	Eingeleitet	Redburn Atlantic	Buy
2025-03-04	Herabstufung	Citigroup	Buy → Neutral
2025-01-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-12-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Fortgesetzt	Jefferies	Buy
2024-10-23	Hochstufung	Robert W. Baird	Neutral → Outperform
2024-08-28	Fortgesetzt	Evercore ISI	In-line
2024-07-10	Hochstufung	Citigroup	Neutral → Buy
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2024-02-07	Hochstufung	Jefferies	Hold → Buy
2024-01-03	Eingeleitet	Barclays	Equal Weight
2023-12-12	Hochstufung	BofA Securities	Neutral → Buy
2023-06-29	Eingeleitet	Piper Sandler	Neutral
2023-05-02	Herabstufung	BofA Securities	Buy → Neutral
2023-04-03	Hochstufung	Citigroup	Sell → Neutral
2023-01-23	Eingeleitet	Evercore ISI	In-line
2022-11-17	Herabstufung	Citigroup	Neutral → Sell
2022-08-22	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-04-04	Herabstufung	Citigroup	Buy → Neutral
2022-02-23	Herabstufung	UBS	Buy → Neutral
2022-02-02	Herabstufung	Jefferies	Buy → Hold
2022-01-28	Herabstufung	Deutsche Bank	Buy → Hold
2021-05-04	Hochstufung	UBS	Neutral → Buy
2021-03-12	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-10-21	Hochstufung	Argus	Hold → Buy
2020-07-29	Hochstufung	KeyBanc Capital Markets	Sector Weight → Overweight
2020-07-14	Hochstufung	BofA Securities	Neutral → Buy
2020-06-09	Hochstufung	Wells Fargo	Underweight → Equal Weight
2020-06-02	Hochstufung	Deutsche Bank	Hold → Buy
2020-04-28	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-04-27	Hochstufung	Citigroup	Neutral → Buy
2020-04-27	Hochstufung	Wolfe Research	Underperform → Peer Perform
2020-03-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-01-08	Eingeleitet	Wells Fargo	Underweight
2020-01-07	Herabstufung	Barclays	Overweight → Equal Weight
2019-12-19	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-07-15	Herabstufung	Goldman	Neutral → Sell
2019-04-02	Hochstufung	Jefferies	Hold → Buy
2019-03-18	Fortgesetzt	Credit Suisse	Neutral
2019-01-31	Herabstufung	Argus	Buy → Hold
2019-01-17	Eingeleitet	UBS	Neutral
2019-01-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2018-12-03	Herabstufung	BofA/Merrill	Buy → Neutral
2018-11-30	Herabstufung	Goldman	Buy → Neutral

Alle ansehen

Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten

09:07 AM

Quest Diagnostics (DGX) Sees Premarket Surge Amid Market Volatility - GuruFocus

09:07 AM

Apr 18, 2026

Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Apr 18, 2026

Apr 17, 2026

Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2026

Apr 16, 2026

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers - ChartMill

Apr 16, 2026

Apr 15, 2026

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Apr 15, 2026

Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings - Yahoo Finance

Apr 15, 2026

Quest Diagnostics Mirrors S&P 500 Index Sector Momentum Clearly - Kalkine Media

Apr 15, 2026

Apr 14, 2026

Baird Adjusts Price Target on Quest Diagnostics to $224 From $219, Maintains Neutral Rating - marketscreener.com

Apr 14, 2026

Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Apr 14, 2026

Patton Fund Management Inc. Has $5.56 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat

Apr 14, 2026

Quest Diagnostics Incorporated $DGX Shares Sold by Atwater Malick LLC - MarketBeat

Apr 14, 2026

Quest Diagnostics (DGX) to Release Earnings on Tuesday - MarketBeat

Apr 14, 2026

Apr 10, 2026